Outcome and Prognostic Factors for Patients Who Relapse after Allogeneic Hematopoietic Stem Cell Transplantation Gita Thanarajasingam, Haesook T. Kim, Corey Cutler, Vincent T. Ho, John Koreth, Edwin P. Alyea, Joseph H. Antin, Robert J. Soiffer, Philippe Armand Biology of Blood and Marrow Transplantation Volume 19, Issue 12, Pages 1713-1718 (December 2013) DOI: 10.1016/j.bbmt.2013.09.011 Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 1 prOS stratified by risk score. (A) prOS in the main cohort of 351 patients. (B) prOS in a historical cohort of 276 patients. Biology of Blood and Marrow Transplantation 2013 19, 1713-1718DOI: (10.1016/j.bbmt.2013.09.011) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 2 prOS survival stratified by postrelapse treatment. Biology of Blood and Marrow Transplantation 2013 19, 1713-1718DOI: (10.1016/j.bbmt.2013.09.011) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions